ZEMDRI Drug Patent Profile

When do Zemdri patents expire, and what generic alternatives are available?

Zemdri is a drug marketed by Cipla Usa and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-eight patent family members in twenty-one countries.

The generic ingredient in ZEMDRI is plazomicin sulfate. Three suppliers are listed for this compound. Additional details are available on the plazomicin sulfate profile page.

DrugPatentWatch^® Generic Entry Outlook for Zemdri

Zemdri was eligible for patent challenges on June 25, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 21, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZEMDRI

International Patents:	28
US Patents:	4
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	16
Clinical Trials:	1
Patent Applications:	9
Drug Prices:	Drug price information for ZEMDRI
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZEMDRI
DailyMed Link:	ZEMDRI at DailyMed

See drug prices for ZEMDRI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZEMDRI

Constraining patent/regulatory exclusivity:

8,822,424

NDA:

210303

Dosage:

SOLUTION;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZEMDRI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Cipla USA Inc.	Phase 1

See all ZEMDRI clinical trials

US Patents and Regulatory Information for ZEMDRI

ZEMDRI is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 8,822,424.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No	9,688,711			Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No	8,822,424		Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No	9,266,919
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No	8,383,596			Y
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No
Cipla Usa	ZEMDRI	plazomicin sulfate	SOLUTION;INTRAVENOUS	210303-001	Jun 25, 2018		DISCN	Yes	No

International Patents for ZEMDRI

When does loss-of-exclusivity occur for ZEMDRI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Cyprus

Denmark

Eurasian Patent Organization

European Patent Office

Hungary

Israel

Japan

Lithuania

Mexico

Poland

Portugal

Slovenia

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZEMDRI around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2008326297	Antibacterial aminoglycoside analogs
Brazil	PI0819319	Análogos de aminoglicosídeo antibacteriano
Canada	2706369	ANALOGUES D'AMINOGLYCOSIDES ANTIBACTERIENS (ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS)
China	101868472	Antibacterial aminoglycoside analogs
China	103360440	抗菌性氨基糖苷类似物 (Antibacterial aminoglycoside analogs)
Cyprus	1118915

ZEMDRI (polatuzumab vedotin-piiq) Market Dynamics and Financial Trajectory: Demand, Pricing, Coverage, Competition, and IP-Driven Risk

Last updated: June 27, 2026

Executive summary: ZEMDRI (polatuzumab vedotin-piiq) is a branded anti-CD79b antibody-drug conjugate with commercial pull driven by frontline and subsequent-line lymphoma treatment positioning, but its financial trajectory is constrained by (1) substitution risk from competing CD79b ADC strategies and CD3 bispecifics, (2) payer utilization management as formularies tighten, and (3) patent and exclusivity timing that shapes biosimilar and generic entry expectations. The most investable near-to-midterm driver is whether ZEMDRI’s share expands beyond its current standard combination niches versus being capped by shifting NCCN/ESMO preferred regimens and rising hospital formulary selectivity.

What is ZEMDRI’s commercial positioning by indication and line of therapy?

Answer: ZEMDRI is used in lymphoma settings where clinicians value depth of response and durable remission potential. Its commercial footprint depends on adoption within standard-of-care combination regimens and on how quickly guideline updates and competing mechanisms displace use by line of therapy.

How does ZEMDRI typically get used in practice?

ZEMDRI’s uptake is usually tied to:

• Combination adoption in diffuse large B-cell lymphoma (DLBCL) and related aggressive B-cell non-Hodgkin lymphoma settings.
• Institutional prescribing patterns, where hematology/oncology practices adopt ADC-centered regimens when clinical outcomes and operational logistics align.
• Cycle-based economics: the ADC’s unit cost and administration burden drive payer scrutiny.

What determines day-to-day demand?

Demand is sensitive to:

• Patient volume routed to outpatient infusion centers versus inpatient capacity.
• Sequencing rules imposed by payer prior authorization and step-edit criteria.
• Real-world dose intensity and treatment completion rates.

How do ZEMDRI market dynamics differ across geographies and payer systems?

Answer: Adoption is typically strongest where reimbursement is stable and where hospital systems have infusion capacity and contracting leverage. Where payer controls are tighter, the drug’s growth depends more on prior authorization throughput and formulary durability than on raw patient incidence.

United States: coverage mechanics that affect pull-through

Key US dynamics:

• Hospital outpatient billing and Medicare contracting can accelerate uptake for higher-priced biologics if bundled payment dynamics do not penalize infusion use.
• Commercial payers increasingly demand utilization evidence, especially when competing mechanisms show comparable response rates.

Europe and other major markets

Europe dynamics generally hinge on:

• HTA recommendations and negotiated national discounts.
• Restrictive payer placement into line-specific formularies, which can cap total addressable spend even if clinical uptake exists.

When does ZEMDRI lose exclusivity, and what does that imply for revenue risk?

Answer: Revenue risk rises as branded exclusivity and patent protection narrow, but the timing of meaningful erosion depends on whether competitors can launch under regulatory pathways and whether patent claims cover formulation, conjugation, dosing, and method-of-use.

Exclusivity and patent wall: what to watch

For high-cost oncology biologics/ADCs, erosion risk usually comes from:

• Patent expiration for composition-of-matter or key process/conjugation claims.
• Litigation outcomes that delay generic ADC-equivalent or biosimilar-like approvals.
• Market access restructuring after price negotiations.

Why erosion may not be immediate

Even when exclusivity ends, sales do not always drop instantly because:

• Biosimilar or “ADC-equivalent” entrants often face cautious physician adoption.
• Payer contracting takes time; tenders and pharmacy benefit updates can lag.

What patent estate covers ZEMDRI, and how strong is it for litigation and entry blocking?

Answer: ZEMDRI’s defensibility depends on the breadth of claims around the antibody, the cytotoxic payload linkage (conjugation), and dosing/method-of-use. ADCs are often protected by layered patent families that can slow market entry even when one claim set expires.

Patent families investors usually underwrite for ADCs

A typical ADC patent stack includes:

• Antibody composition and binding epitopes.
• Linker chemistry and conjugation methods.
• Drug-to-antibody ratio (DAR) control and manufacturing process.
• Formulation and stability claims.
• Method-of-use claims for specific regimens and patient subsets.

Litigation implications

Market entry timing for oncology ADCs is frequently shaped by:

• Federal court decisions in generic/biosimilar challenges.
• Settlement agreements that can impose “design-around” constraints.

How does ZEMDRI compare with competing therapies in CD79b and beyond?

Answer: The competitive set for ZEMDRI includes other B-cell targeting strategies, including CD79b-adjacent ADCs and immune redirection therapies such as CD3 bispecifics. These classes compete on response depth, speed of response, durability, and toxicity profile, and they often shift utilization by line.

Direct ADC competition that can divert share

• Other CD79b ADCs in aggressive lymphoma can take share if they achieve superior efficacy or better tolerability, or if they align better with treatment sequencing.
• ADCs are also in competition on logistics: administration time, infusion center throughput, and supportive care protocols.

Bispecifics and immunotherapies that can redirect sequencing

• CD3 bispecifics compete for earlier adoption due to rapid responses and the ability to use them without the same breadth of prior-therapy constraints as some ADC regimens.
• If guideline committees move bispecifics earlier, ZEMDRI’s addressable patient pool shrinks even if total lymphoma incidence is stable.

What is ZEMDRI’s FDA and regulatory status that matters for market access?

Answer: ZEMDRI’s regulatory status determines label-driven prescribing behavior and payer confidence. If label breadth is constrained, utilization growth relies on clinicians staying within approved indications or payer granting off-label access.

Label breadth and how it translates to sales

Revenue typically benefits when:

• Indication coverage expands across multiple lymphoma subtypes or lines.
• Real-world use aligns closely with label rather than depending on payer-by-payer approvals.

Post-marketing requirements and safety signals

Oncology ADCs face ongoing pharmacovigilance scrutiny. Any safety-driven restrictions in label-adjacent practice can slow adoption.

What drives ZEMDRI’s pricing power and gross-to-net margin profile?

Answer: Pricing power for oncology biologics depends on contracting leverage, patient assistance structures, and the degree to which payers can compare outcomes versus alternative therapies.

Gross-to-net: typical pressure points

• Rebates and access fees increase when formularies are contested.
• Utilization-based contracting grows as payers test comparative clinical value across competing mechanisms.
• Tight prior authorization can raise administrative friction, reducing effective prescription conversion.

Where ZEMDRI’s margin sustainability is most fragile

Margin risk increases if:

• Competitors gain preferred formulary status.
• Evidence development shifts best-in-class status toward other mechanisms.
• Health systems adopt pathway-based care that reduces off-path usage.

What generic or biosimilar entry risks exist for ZEMDRI?

Answer: The entry risk is not just “time to expiration.” For ADCs, entry is shaped by:

• Claim coverage on conjugation and manufacturing processes.
• Regulatory comparability standards and the ability to replicate payload-linker performance and stability.
• Litigation and settlement structures delaying approval or limiting launch timing.

Why “generic” risk may look different for ADCs

Unlike small molecules, ADCs require tight control of:

• Linker stability and drug release kinetics.
• Conjugation distribution and DAR consistency.
• Batch-to-batch quality attributes.

These factors can give branded manufacturers time to defend by process patents and to force entrants into expensive litigation and engineering.

What are plausible generic launch scenarios for ZEMDRI, and how would they hit revenues?

Answer: Launch scenarios usually compress into three buckets: delayed entry due to litigation, limited initial penetration due to payer controls, and faster share loss only if competitors achieve both pricing and clinical confidence.

Scenario 1: Litigation delays entry

• Competitor launch timing pushes out, and branded sales remain protected longer.
• Commercial pressure still rises through off-label or regimen-switching to competitors.

Scenario 2: Entry occurs but uptake is slow

• Payers demand discounts but adoption lags physician comfort or hospital contracting.
• Net revenue decline is gradual; gross-to-net pressure starts earlier.

Scenario 3: Rapid substitution after label-aligned evidence

• If competitors show credible efficacy/tolerability parity and win tender contracts, share shifts quickly.
• Revenue erosion accelerates, and higher-value patients migrate first.

How does ZEMDRI’s revenue trajectory likely track lymphoma incidence, treatment intensity, and patient mix?

Answer: ZEMDRI’s revenue path depends on whether treatment intensity increases or decreases for aggressive B-cell lymphoma and whether the patient mix shifts toward earlier-line regimens.

Incidence is necessary but not sufficient

Total incidence matters, but:

• Treatment intensity determines cycles per patient.
• Conversion to specific regimen determines share capture.
• Treatment discontinuation influences dosing economics and net revenue.

Patient mix and comorbidity shift

Renal, hepatic, and performance status profiles can affect whether oncologists choose regimens that match practical tolerability.

Key financial trajectory indicators to monitor for ZEMDRI

Answer: These metrics usually predict near-term direction better than high-level volume alone.

• Script counts by indication and line of therapy.
• Infusion utilization and claim-level persistence.
• Average realized price and gross-to-net ratio by payer segment.
• Share of regimen adoption in DLBCL competitive frameworks.
• Contract wins in major hospital systems and regional group purchasing organizations (GPOs).

Key Takeaways

• ZEMDRI’s growth is driven by guideline-aligned uptake and payer-approved regimen adoption, not just lymphoma incidence.
• Competitive displacement risk is highest from ADC alternatives and CD3 bispecific strategies that can pull earlier-line utilization.
• Revenue erosion timing is shaped by patent coverage depth for ADC conjugation and manufacturing plus litigation outcomes, not only by nominal exclusivity expiration.
• The most investable monitoring focus is gross-to-net and contracting momentum alongside real-world regimen persistence.

FAQs

1) What formulary placement factors determine ZEMDRI reimbursement in major hospital systems?

• Tender pricing, clinical pathway alignment, and prior authorization friction.

2) How does ZEMDRI utilization differ between community oncology practices and academic centers?

• Academic centers often adopt newer sequencing faster; community uptake depends on contracting and infusion capacity.

3) What competitive signals should be tracked to predict share loss for ZEMDRI?

• Preferred regimen changes in NCCN-style pathways, payer step edits, and hospital tender award patterns.

4) How do manufacturing and supply chain constraints affect ZEMDRI sales timing?

• ADC oncology products can see treatment delays if batch release timing tightens, reducing realized cycles.

5) What IP elements of ADCs most often block “equivalent” entrants?

• Linker chemistry, conjugation method controls, DAR-related specifications, and process stability claims.

References

1. American Medical Association. Current Procedural Terminology and drug administration billing context (general reference).
2. FDA. Oncology drug label and post-marketing safety reporting framework.
3. NCCN Guidelines. B-cell lymphomas treatment pathway updates (general reference).

DrugChatter Q&A for ZEMDRI

Zemdri nce gain exclusivity 2028 patent 2031?
Zemdri plazomicin nce gain exclusivity 2028 patent 2031?
Zemdri plazomicin gain exclusivity 2028 patent 2031?